These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 15307028)

  • 1. Infections due to Aspergillus terreus: a multicenter retrospective analysis of 83 cases.
    Steinbach WJ; Benjamin DK; Kontoyiannis DP; Perfect JR; Lutsar I; Marr KA; Lionakis MS; Torres HA; Jafri H; Walsh TJ
    Clin Infect Dis; 2004 Jul; 39(2):192-8. PubMed ID: 15307028
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis.
    Herbrecht R; Denning DW; Patterson TF; Bennett JE; Greene RE; Oestmann JW; Kern WV; Marr KA; Ribaud P; Lortholary O; Sylvester R; Rubin RH; Wingard JR; Stark P; Durand C; Caillot D; Thiel E; Chandrasekar PH; Hodges MR; Schlamm HT; Troke PF; de Pauw B;
    N Engl J Med; 2002 Aug; 347(6):408-15. PubMed ID: 12167683
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epidemiology and outcome of invasive fungal infection in adult hematopoietic stem cell transplant recipients: analysis of Multicenter Prospective Antifungal Therapy (PATH) Alliance registry.
    Neofytos D; Horn D; Anaissie E; Steinbach W; Olyaei A; Fishman J; Pfaller M; Chang C; Webster K; Marr K
    Clin Infect Dis; 2009 Feb; 48(3):265-73. PubMed ID: 19115967
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Strategy of following voriconazole versus amphotericin B therapy with other licensed antifungal therapy for primary treatment of invasive aspergillosis: impact of other therapies on outcome.
    Patterson TF; Boucher HW; Herbrecht R; Denning DW; Lortholary O; Ribaud P; Rubin RH; Wingard JR; DePauw B; Schlamm HT; Troke P; Bennett JE; ;
    Clin Infect Dis; 2005 Nov; 41(10):1448-52. PubMed ID: 16231256
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Changes in causes of death over time after treatment for invasive aspergillosis.
    Wingard JR; Ribaud P; Schlamm HT; Herbrecht R
    Cancer; 2008 May; 112(10):2309-12. PubMed ID: 18338758
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Outcome and medical costs of patients with invasive aspergillosis and acute myelogenous leukemia-myelodysplastic syndrome treated with intensive chemotherapy: an observational study.
    Slobbe L; Polinder S; Doorduijn JK; Lugtenburg PJ; el Barzouhi A; Steyerberg EW; Rijnders BJ
    Clin Infect Dis; 2008 Dec; 47(12):1507-12. PubMed ID: 18990068
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Voriconazole treatment for subacute invasive and chronic pulmonary aspergillosis.
    Sambatakou H; Dupont B; Lode H; Denning DW
    Am J Med; 2006 Jun; 119(6):527.e17-24. PubMed ID: 16750972
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Treatment of invasive fungal infections with voriconazole. Evaluation of experience with compassionate use of voriconazole in Spain].
    Díaz Pedroche C; Cisneros JM; Lumbreras C; Aguado JM;
    Rev Esp Quimioter; 2005 Jun; 18(2):149-58. PubMed ID: 16130037
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Resource use and cost of treatment with voriconazole or conventional amphotericin B for invasive aspergillosis.
    Wingard JR; Herbrecht R; Mauskopf J; Schlamm HT; Marciniak A; Roberts CS
    Transpl Infect Dis; 2007 Sep; 9(3):182-8. PubMed ID: 17605747
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Experience with voriconazole in invasive aspergillosis].
    Thiel E; Schwartz S
    Mycoses; 2003; 46 Suppl 2():3-7. PubMed ID: 15055137
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis.
    Denning DW; Ribaud P; Milpied N; Caillot D; Herbrecht R; Thiel E; Haas A; Ruhnke M; Lode H
    Clin Infect Dis; 2002 Mar; 34(5):563-71. PubMed ID: 11807679
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Surveillance of invasive mold infections in lung transplant recipients: effect of antimycotic prophylaxis with itraconazole and voriconazole].
    Mattner F; Chaberny IF; Weissbrodt H; Fischer S; Gastmeier P; Haubitz B; Gottlieb J; Mattner L; Strueber M
    Mycoses; 2005; 48 Suppl 1():51-5. PubMed ID: 15826288
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intravitreal voriconazole for the treatment of endogenous Aspergillus endophthalmitis.
    Kramer M; Kramer MR; Blau H; Bishara J; Axer-Siegel R; Weinberger D
    Ophthalmology; 2006 Jul; 113(7):1184-6. PubMed ID: 16713628
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epidemiology and outcome of infections due to Aspergillus terreus: 10-year single centre experience.
    Lass-Flörl C; Griff K; Mayr A; Petzer A; Gastl G; Bonatti H; Freund M; Kropshofer G; Dierich MP; Nachbaur D
    Br J Haematol; 2005 Oct; 131(2):201-7. PubMed ID: 16197450
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of lung resection and voriconazole for successful treatment of invasive pulmonary Aspergillus ustus infection.
    Azzola A; Passweg JR; Habicht JM; Bubendorf L; Tamm M; Gratwohl A; Eich G
    J Clin Microbiol; 2004 Oct; 42(10):4805-8. PubMed ID: 15472346
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Topical voriconazole solution for cutaneous aspergillosis in a pediatric patient after bone marrow transplant.
    Klein KC; Blackwood RA
    Pediatrics; 2006 Aug; 118(2):e506-8. PubMed ID: 16816005
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Invasive aspergillosis in a tertiary-care hospital in Thailand.
    Kiertiburanakul S; Thibbadee C; Santanirand P
    J Med Assoc Thai; 2007 May; 90(5):895-902. PubMed ID: 17596043
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Incidence of invasive aspergillosis among allogeneic hematopoietic stem cell transplant patients receiving voriconazole prophylaxis.
    Siwek GT; Pfaller MA; Polgreen PM; Cobb S; Hoth P; Magalheas-Silverman M; Diekema DJ
    Diagn Microbiol Infect Dis; 2006 Jul; 55(3):209-12. PubMed ID: 16626917
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Aspergillus terreus: an emerging amphotericin B-resistant opportunistic mold in patients with hematologic malignancies.
    Hachem RY; Kontoyiannis DP; Boktour MR; Afif C; Cooksley C; Bodey GP; Chatzinikolaou I; Perego C; Kantarjian HM; Raad II
    Cancer; 2004 Oct; 101(7):1594-600. PubMed ID: 15378491
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical application of voriconazole concentrations in the treatment of invasive aspergillosis.
    Howard A; Hoffman J; Sheth A
    Ann Pharmacother; 2008 Dec; 42(12):1859-64. PubMed ID: 19017830
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.